Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

PURPOSE: Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody–dr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rosenberg, Jonathan E., O’Donnell, Peter H., Balar, Arjun V., McGregor, Bradley A., Heath, Elisabeth I., Yu, Evan Y., Galsky, Matthew D., Hahn, Noah M., Gartner, Elaina M., Pinelli, Juan M., Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784850/
https://ncbi.nlm.nih.gov/pubmed/31356140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados